Postoperative TSH Levels Did Not Affect Recurrence After Thyroid Lobectomy in Patients With Papillary Thyroid Cancer
Thyroid World Congress ePoster Library. Kim M. 06/22/19; 272141; 24
Min Joo Kim
Min Joo Kim
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)
Background/Purpose: Thyroid-stimulating hormone (TSH) suppression is recommended for patients who undergo thyroidectomy for differentiated thyroid cancer (DTC). However, the impact of TSH suppression on clinical outcomes in low-risk DTC remains uncertain. Therefore, we investigated the effects of postoperative TSH levels on recurrence in patients with low-risk DTC after thyroid lobectomy

Methods: Patients (n = 1528) who underwent thyroid lobectomy for papillary thyroid carcinoma between 2000 and 2012 were included in this study. According to the mean, median, and dominant TSH values during the entire follow-up period of 5 years, patients were divided into four groups (<0.5 mIU/L, 0.5-1.9 mIU/L, 2.0-4.4 mIU/L, and ≥4.5 mIU/L). Recurrence-free survival was compared among the groups.

Results: During the 5.6 years of follow-up, 21 (1.4%) patients experienced recurrence. Mean TSH levels were within the recommended low-normal range (0.5-1.9 mIU/L) during the total follow-up period or 5 years in 38.1% or 36.0% of patients. The mean, median, and dominant TSH values did not affect recurrence-free survival. Adjustment for other risk factors did not alter the results.

Discussion & Conclusion: Serum TSH levels did not affect short-term recurrence in patients with low-risk DTC after thyroid lobectomy. TSH suppression should be conducted more selectively.


 
Background/Purpose: Thyroid-stimulating hormone (TSH) suppression is recommended for patients who undergo thyroidectomy for differentiated thyroid cancer (DTC). However, the impact of TSH suppression on clinical outcomes in low-risk DTC remains uncertain. Therefore, we investigated the effects of postoperative TSH levels on recurrence in patients with low-risk DTC after thyroid lobectomy

Methods: Patients (n = 1528) who underwent thyroid lobectomy for papillary thyroid carcinoma between 2000 and 2012 were included in this study. According to the mean, median, and dominant TSH values during the entire follow-up period of 5 years, patients were divided into four groups (<0.5 mIU/L, 0.5-1.9 mIU/L, 2.0-4.4 mIU/L, and ≥4.5 mIU/L). Recurrence-free survival was compared among the groups.

Results: During the 5.6 years of follow-up, 21 (1.4%) patients experienced recurrence. Mean TSH levels were within the recommended low-normal range (0.5-1.9 mIU/L) during the total follow-up period or 5 years in 38.1% or 36.0% of patients. The mean, median, and dominant TSH values did not affect recurrence-free survival. Adjustment for other risk factors did not alter the results.

Discussion & Conclusion: Serum TSH levels did not affect short-term recurrence in patients with low-risk DTC after thyroid lobectomy. TSH suppression should be conducted more selectively.


 
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings